Genix Pharmaceuticals Corporation
GENX.V
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.00K | 15.70K | 22.30K | 23.60K | 22.50K |
| Depreciation & Amortization | -- | -- | 200.00 | 200.00 | 200.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.00K | 15.70K | 22.50K | 23.80K | 22.70K |
| Operating Income | -17.00K | -15.70K | -22.50K | -23.80K | -22.70K |
| Income Before Tax | -57.30K | -38.10K | -66.50K | -60.80K | -36.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.30K | -38.10K | -66.50K | -60.80K | -36.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.30K | -38.10K | -66.50K | -60.80K | -36.60K |
| EBIT | -17.00K | -15.70K | -22.50K | -23.80K | -22.70K |
| EBITDA | -- | -- | -22.30K | -23.60K | -22.50K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 61.22M | 61.22M | 60.50M | 59.22M | 59.22M |
| Average Diluted Shares Outstanding | 61.22M | 61.22M | 60.50M | 59.22M | 59.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |